Morgan Stanley’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.7M | Sell |
878,746
-818,811
| -48% | -$10.9M | ﹤0.01% | 3294 |
|
|
2025
Q1 | $17.3M | Buy |
1,697,557
+1,040,756
| +158% | +$10.6M | ﹤0.01% | 2840 |
|
|
2024
Q4 | $10.4M | Buy |
656,801
+291,504
| +80% | +$4.61M | ﹤0.01% | 3374 |
|
|
2024
Q3 | $21.2M | Buy |
365,297
+29,628
| +9% | +$1.72M | ﹤0.01% | 2745 |
|
|
2024
Q2 | $15.3M | Buy |
335,669
+46,512
| +16% | +$2.13M | ﹤0.01% | 2951 |
|
|
2024
Q1 | $19.1M | Sell |
289,157
-1,561,619
| -84% | -$103M | ﹤0.01% | 2750 |
|
|
2023
Q4 | $73.6M | Buy |
1,850,776
+1,402,075
| +312% | +$55.7M | ﹤0.01% | 2039 |
|
|
2023
Q3 | $14.3M | Buy |
448,701
+398,903
| +801% | +$12.7M | ﹤0.01% | 2789 |
|
|
2023
Q2 | $2M | Sell |
49,798
-91,172
| -65% | -$3.66M | ﹤0.01% | 4427 |
|
|
2023
Q1 | $6.02M | Sell |
140,970
-1,991
| -1% | -$85K | ﹤0.01% | 3621 |
|
|
2022
Q4 | $6.86M | Buy |
142,961
+81,440
| +132% | +$3.91M | ﹤0.01% | 3457 |
|
|
2022
Q3 | $2.31M | Sell |
61,521
-58,277
| -49% | -$2.19M | ﹤0.01% | 4321 |
|
|
2022
Q2 | $3.31M | Buy |
119,798
+67,970
| +131% | +$1.88M | ﹤0.01% | 4120 |
|
|
2022
Q1 | $2.82M | Buy |
51,828
+44,687
| +626% | +$2.43M | ﹤0.01% | 4250 |
|
|
2021
Q4 | $417K | Sell |
7,141
-73,071
| -91% | -$4.27M | ﹤0.01% | 5656 |
|
|
2021
Q3 | $3.17M | Buy |
80,212
+57,232
| +249% | +$2.26M | ﹤0.01% | 4169 |
|
|
2021
Q2 | $976K | Buy |
22,980
+22,693
| +7,907% | +$964K | ﹤0.01% | 5094 |
|
|
2021
Q1 | $18K | Sell |
287
-75,348
| -100% | -$4.73M | ﹤0.01% | 6758 |
|
|
2020
Q4 | $5.34M | Buy |
75,635
+75,008
| +11,963% | +$5.29M | ﹤0.01% | 3191 |
|
|
2020
Q3 | $24K | Sell |
627
-1,526
| -71% | -$58.4K | ﹤0.01% | 5994 |
|
|
2020
Q2 | $81K | Buy |
+2,153
| New | +$81K | ﹤0.01% | 5497 |
|